

United States Senate

WASHINGTON, DC 20510-6200

November 17, 2025

President Donald J. Trump
1600 Pennsylvania Avenue NW
Washington, DC 20500

Dear President Trump,

We urge the Trump Administration to immediately release the 2027 Medicare-negotiated drug prices. In 2022, Democrats—without a single Republican vote—gave Medicare the long overdue authority to negotiate lower drug prices. Your Administration has withheld these prices from the public for nearly a month without explanation.

Meanwhile, you continue to host flashy Oval Office press conferences announcing so-called “historic” drug pricing deals standing beside pharmaceutical company CEOs. Last week, you announced that Medicare will pay a \$245 price on Ozempic without acknowledging that, thanks to the Democrats’ Medicare drug price negotiation law, the price of Ozempic for Medicare has already been negotiated by career staff at the Centers for Medicare & Medicaid Services (CMS). During another one of these events in October, Robert F. Kennedy, Jr. even went so far as to suggest that the discounts achieved under the Trump Administration’s voluntary agreements outperform Medicare drug price negotiation.¹ We are skeptical, and challenge you to release the 2027 Medicare-negotiated prices. This will lay bare the facts: Medicare drug price negotiations meaningfully lowers the price of prescription drugs, unlike your opaque Oval Office announcements.

Lower Medicare-negotiated drug prices will save seniors and taxpayers billions of dollars. In January 2026, lower Medicare-negotiated prices for the first ten drugs will take effect, which will save an estimated \$6 billion for taxpayers and \$1.5 billion in out-of-pocket costs for seniors and people with disabilities on Medicare.² These ten medications, taken by more than 8 million Medicare beneficiaries, treat conditions like diabetes, cancer, blood clots, and heart disease.

CMS finished negotiating the prices of the next 15 drugs on October 15, 2025. The next 15 drugs, for which lower Medicare-negotiated pricing will take effect in January 2027, include blockbuster medications like Ozempic and Xtandi. Medicare has spent over \$40 billion during a one-year period on these next 15 drugs alone.³ The Trump Administration could release concrete

¹ [Roll Call Factbase - Remarks: Donald Trump Announces a New Prescription Drug Discount - October 10, 2025](#)

² <https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026>


³ <https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower>

information *today* letting American seniors and taxpayers know how much they are going to save on these drugs.

By contrast, the American public still has very few details about how the deals you are striking with pharmaceutical company executives will lower their drug costs. In fact, the most concrete drug pricing policy the Trump Administration has enacted was an \$8.8 billion windfall for pharmaceutical corporations in the Republican budget bill (H.R. 1), bailing some of the world's best-selling drugs out of Medicare negotiation. Because of this Republican policy, seniors with cancer will continue to pay sky-high prices for life-saving, blockbuster drugs like Keytruda, Opdivo, Darzalex, and more.

Last week's election results show that voters are fed up with the constant bait-and-switch from the Trump Administration on affordability. Your false promises on drug prices follow the same tired pattern of big talk about lowering costs without delivering. It is time to release the 2027 Medicare-negotiated drug prices so the American people can learn what to expect about their drug costs and see which party's drug pricing policies actually make a difference for their pocketbook.


Sincerely,




Ron Wyden
United States Senator
Ranking Member, Committee
on Finance



Charles E. Schumer
United States Senator



Ben Ray Lujan
United States Senator



Peter Welch
United States Senator



Raphael Warnock
United States Senator



Sheldon Whitehouse
United States Senator



Kirsten Gillibrand
United States Senator
Ranking Member, Special
Committee on Aging



Catherine Cortez Masto
United States Senator



Cory A. Booker
United States Senator